News and challenges in the treatment of hepatitis C in liver transplantation

Liver International

Volumn 36, Issue , 2016, Pages 34-42

  Coilly, Audrey ^a,b,c,d   Roche, Bruno ^a,c,d   Duclos Vallée, Jean Charles ^a,b,c,d   Samuel, Didier ^a,b,c,d  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d DHU Hepatinov   (France)

Author keywords

Antiviral therapy; Decompensated cirrhosis; Direct acting antivirals; Drug drug interactions; Hepatitis C; Liver transplantation

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON;

ANTIVIRAL THERAPY; CHOLESTATIC HEPATITIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG INTERACTION; GRAFT RECIPIENT; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MIXED INFECTION; PATIENT SAFETY; PERSONAL EXPERIENCE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RECURRENT DISEASE; REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; COMPLICATION; END STAGE LIVER DISEASE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE; RIBAVIRIN;

EID: 84952802256     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13017     Document Type: Review

References (39)

1. Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol 2013; 58: 287-96.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
3. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-6.
4. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-8.
5. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.
6. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-28.
7. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
8. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-42 e4.
9. Coilly A, Dumortier J, Botta-Fridlund D, et al. multicenter experience with boceprevir or telaprevir to treat hepatitis C recurrence after liver transplantation: when present becomes past, what lessons for future? PLoS ONE 2015; 10: e0138091.
10. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-7 e1.
11. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-59.
12. Manns M, Forns X, Samuel D, et al. G02: ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective solar 2 trial. J Hepatol 2015; 62: S187-8.
13. Poordad F, Schiff ER, Vierling JM, et al. LO8: daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study. J Hepatol 2015; 62: S261-2.
14. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.
15. Foster GR, McLauchlan J, Irving W, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol 2015; 62: S190-1.
16. Reddy R, Lim JK, Kuo A, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience. J Hepatol 2015; 62: S193.
17. Aqel BA, Pungpapong S, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62: 1004-12.
18. Coilly A, Pageaux GP, Houssel-Debry P, et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA? AASLD 2015, San Francisco, USA, 11-16 November 2015.
19. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
20. Perumpail RB, Wong RJ, Ha LD, et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis 2015; 17: 275-8.
21. Roth D, Nelson D, Bruchfeld A, et al. LP02: C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. J Hepatol 2015; 62: S263-4.
22. Lawitz E, Poordad F, Gutierrez J, et al. LP07: simeprevir (SMV) plus daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: interim results from the phase II impact study. J Hepatol 2015; 62: S266-7.
23. Zhang N, Lu W, Liang S, Neff G. P276: outcomes in patients with small hepatocellular carcinoma and chronic hepatitis C infection treated with RFA and antiviral therapy. J Hepatol 2014; 58: S117.
24. Toso C, Dupuis-Lozeron E, Majno P, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56: 149-56.
25. Afdhal N, Everson GT, Calleja JL, et al. LP13: effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol 2015; 62: S269-70.
26. Ruiz I, Feray C, Pawlotsky JM, Hezode C. Patients with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl 2015; 21: 408-9.
27. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-17.
28. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-82.
29. Brown R Jr, Reddy KR, O'Leary JG, et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. AASLD 2014, Boston, MA, USA, 7-11 November 2014.
30. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-6.
31. Coilly A, Fougerou C, De Ledinghen V, et al. G15: the association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: results from a large french prospective multicentric ANRS CO23 CUPILT cohort. J Hepatol 2015; 62: S236-7.
32. Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015; 149: 1378-1380.
33. Forns X, Berenguer M, Herzer K, et al. O004: on-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): interim data from the phase II saturn study. J Hepatol 2015; 62: S191-2.
34. Antonini TM, Furlan V, Teicher E, et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS 2015; 29: 53-8.
35. Antonini TM, Bedoya JU, Teicher E, et al. P0837: efficacy of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis. J Hepatol 2015; 62: S651.
36. Antonini TM, Sebagh M, Roque-Afonso AM, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 2011; 11: 1686-95.
37. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-94.
38. Leroy V, Dumortier J, Coilly A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015; 13: 1993-2001.
39. Forns X, Mutimer D, Manns M, et al. P0779: ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. J Hepatol 2015; 62: S623.